Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease

M. Contin, R. Riva, P. Martinelli, G. Procaccianti, F. Albani, A. Baruzzi

Research output: Contribution to journalArticle

Abstract

The effect of chronic intake of the anticholinergic drug orphenadrine on the bioavailability of levodopa was studied in six patients with Parkinson's disease. Plasma levodopa profiles and corresponding motor response to a standard dose of levodopa plus an inhibitor of peripheral L-aromatic aminoacid decarboxylase (benserazide) were followed, over a 5-h period, on two different sessions, with and without anticholinergic cotherapy. Six control patients were also included in the study for assessment of intrasubject variability in levodopa absorption under identical conditions. A considerable delay in levodopa absorption was found in one patient, and decreased absorption in an additional two patients while on anticholinergic. Patients' clinical performance corresponded well to plasma levodopa profiles. A significant impairment of basal clinical state was observed in two cases on anticholinergic withdrawal, probably as a result of pharmacodynamic interactions. Our observations suggest that chronic anticholinergic intake may contribute to a less predictable pattern of levodopa absorption and related therapeutic response in some subjects.

Original languageEnglish
Pages (from-to)148-155
Number of pages8
JournalClinical Neuropharmacology
Volume14
Issue number2
Publication statusPublished - 1991

Fingerprint

Cholinergic Antagonists
Levodopa
Parkinson Disease
Therapeutics
Orphenadrine
Benserazide
Carboxy-Lyases
Biological Availability
Pharmaceutical Preparations

Keywords

  • Anticholinergics
  • Antiparkinsonian drugs interaction
  • Levodopa
  • Levodopa bioavailability
  • Orphenadrine

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. / Contin, M.; Riva, R.; Martinelli, P.; Procaccianti, G.; Albani, F.; Baruzzi, A.

In: Clinical Neuropharmacology, Vol. 14, No. 2, 1991, p. 148-155.

Research output: Contribution to journalArticle

@article{8065e15eb6a842ae941e8e783c38c523,
title = "Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease",
abstract = "The effect of chronic intake of the anticholinergic drug orphenadrine on the bioavailability of levodopa was studied in six patients with Parkinson's disease. Plasma levodopa profiles and corresponding motor response to a standard dose of levodopa plus an inhibitor of peripheral L-aromatic aminoacid decarboxylase (benserazide) were followed, over a 5-h period, on two different sessions, with and without anticholinergic cotherapy. Six control patients were also included in the study for assessment of intrasubject variability in levodopa absorption under identical conditions. A considerable delay in levodopa absorption was found in one patient, and decreased absorption in an additional two patients while on anticholinergic. Patients' clinical performance corresponded well to plasma levodopa profiles. A significant impairment of basal clinical state was observed in two cases on anticholinergic withdrawal, probably as a result of pharmacodynamic interactions. Our observations suggest that chronic anticholinergic intake may contribute to a less predictable pattern of levodopa absorption and related therapeutic response in some subjects.",
keywords = "Anticholinergics, Antiparkinsonian drugs interaction, Levodopa, Levodopa bioavailability, Orphenadrine",
author = "M. Contin and R. Riva and P. Martinelli and G. Procaccianti and F. Albani and A. Baruzzi",
year = "1991",
language = "English",
volume = "14",
pages = "148--155",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease

AU - Contin, M.

AU - Riva, R.

AU - Martinelli, P.

AU - Procaccianti, G.

AU - Albani, F.

AU - Baruzzi, A.

PY - 1991

Y1 - 1991

N2 - The effect of chronic intake of the anticholinergic drug orphenadrine on the bioavailability of levodopa was studied in six patients with Parkinson's disease. Plasma levodopa profiles and corresponding motor response to a standard dose of levodopa plus an inhibitor of peripheral L-aromatic aminoacid decarboxylase (benserazide) were followed, over a 5-h period, on two different sessions, with and without anticholinergic cotherapy. Six control patients were also included in the study for assessment of intrasubject variability in levodopa absorption under identical conditions. A considerable delay in levodopa absorption was found in one patient, and decreased absorption in an additional two patients while on anticholinergic. Patients' clinical performance corresponded well to plasma levodopa profiles. A significant impairment of basal clinical state was observed in two cases on anticholinergic withdrawal, probably as a result of pharmacodynamic interactions. Our observations suggest that chronic anticholinergic intake may contribute to a less predictable pattern of levodopa absorption and related therapeutic response in some subjects.

AB - The effect of chronic intake of the anticholinergic drug orphenadrine on the bioavailability of levodopa was studied in six patients with Parkinson's disease. Plasma levodopa profiles and corresponding motor response to a standard dose of levodopa plus an inhibitor of peripheral L-aromatic aminoacid decarboxylase (benserazide) were followed, over a 5-h period, on two different sessions, with and without anticholinergic cotherapy. Six control patients were also included in the study for assessment of intrasubject variability in levodopa absorption under identical conditions. A considerable delay in levodopa absorption was found in one patient, and decreased absorption in an additional two patients while on anticholinergic. Patients' clinical performance corresponded well to plasma levodopa profiles. A significant impairment of basal clinical state was observed in two cases on anticholinergic withdrawal, probably as a result of pharmacodynamic interactions. Our observations suggest that chronic anticholinergic intake may contribute to a less predictable pattern of levodopa absorption and related therapeutic response in some subjects.

KW - Anticholinergics

KW - Antiparkinsonian drugs interaction

KW - Levodopa

KW - Levodopa bioavailability

KW - Orphenadrine

UR - http://www.scopus.com/inward/record.url?scp=0026070503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026070503&partnerID=8YFLogxK

M3 - Article

C2 - 2015611

AN - SCOPUS:0026070503

VL - 14

SP - 148

EP - 155

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -